Compare Globus Medical Inc. Class A Common Stock (GMED) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Direxion Daily S&P 500 Bull 3X Shares trades at $284.03 (market cap $7.36B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Direxion Daily S&P 500 Bull 3X Shares for 33 Days on average.
| GMED | SPXL | |
|---|---|---|
Market Cap | $10.25B | $7.36B |
Volume | 1,108,124 | 1,127,892 |
Sector | Health | Leveraged / Inverse |
52-Week High | $96.82 | $301.38 |
52-Week Low | $58.33 | $170.20 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SPXL trades at $297.37 with no daily change, maintaining a bullish technical stance supported by moving averages. The ETF shows neutral oscillator signals with RSI at 75.74 suggesting potential overbought conditions. Recent news highlights S&P 500 valuation concerns amid strong profit growth expectations of 35% for 2026, though projections slow to 15% for 2027 according to Wall Street analysts.
The ETF's outlook remains tied to S&P 500 performance, with seasonal patterns and earnings growth as key catalysts. Risks include market concentration in top holdings and geopolitical uncertainty. Analyst sentiment is mixed with technical indicators favoring upside while fundamental valuations warrant caution given projected earnings deceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
